The effect of hypertension on serum nitric oxide and vascular endothelial growth factor concentrations. A study in DOCA-Salt hypertensive ovariectomized rats

Regulatory Peptides

Volumn 135, Issue 1-2, 2006, Pages 91-94

  Khazaei, M ^a   Nematbakhsh, M ^b  

^a UNIVERSITY OF BIRJAND   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

Hypertension; Nitric oxide; Vascular endothelial growth factor

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; NITRIC OXIDE; SODIUM CHLORIDE; TAP WATER; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRINKING; ENDOTHELIAL DYSFUNCTION; FEMALE; HYPERTENSION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE; FEMALE; HUMANS; HYPERTENSION; NITRIC OXIDE; OVARIECTOMY; RANDOM ALLOCATION; RATS; SODIUM CHLORIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 33744536421     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.04.003     Document Type: Article

References (33)

1. Luscher T.F. The endothelium and cardiovascular disease-a complex relation. N Engl J Med 330 (1994) 1081-1083
2. Luscher T.F., and Barton M. Biology of the endothelium. Clin Cardiol 20 (1997) II-10
3. Ignarro L.J., Cirino G., Casini A., and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 34 (1999) 879-886
4. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 329 (1993) 2002-2012
5. Gewaltig M.T., and Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55 (2002) 250-260
6. Bates D.O., Hillman N.J., Williams B., Neal C.R., and Pocock T.M. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 200 (2002) 581-597
7. Zachary I. Vascular endothelial growth factor. Int J Biochem Cell Biol 30 (1998) 1169-1174
8. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999) 9-22
9. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
10. Klagsbrun M., and D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7 (1996) 259-270
11. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
12. Nicosia R.F., Nicosia S.V., and Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 145 (1994) 1023-1029
13. Pepper M.S., Ferrara N., Orci L., and Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189 (1992) 824-831
14. Phillips G.D., Stone A.M., Jones B.D., Schultz J.C., Whitehead R.A., and Knighton D.R. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 8 (1994) 961-965
15. Tolentino M.J., Miller J.W., Gragoudas E.S., Chatzistefanou K., Ferrara N., and Adamis A.P. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114 (1996) 964-970
16. Blann A.D., Belgore F.M., Constans J., Conri C., and Lip G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 87 (2001) 1160-1163
17. le Noble F.A., Stassen F.R., Hacking W.J., and Struijker Boudier H.A. Angiogenesis and hypertension. J Hypertens 16 (1998) 1563-1572
18. Huang M., Hester R.L., Coleman T.G., Smith M.J., and Guyton A.C. Development of hypertension in animals with reduced total peripheral resistance. Hypertension 20 (1992) 828-833
19. Nematbakhsh M., and Khazaei M. The effect of estrogen on serum nitric oxide concentrations in normotensive and DOCA Salt hypertensive ovariectomized rats. Clin Chim Acta 344 (2004) 53-57
20. Calver A., Collier J., and Vallance P. Nitric oxide and the control of human vascular tone in health and disease. Eur J Med 2 (1993) 48-53
21. G-monomethyl-l-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 10 (1992) 1025-1031
22. Bragulat E., de la S.A., Antonio M.T., and Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 37 (2001) 444-448
23. Panza J.A., Quyyumi A.A., Brush Jr. J.E., and Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323 (1990) 22-27
24. Panza J.A., Casino P.R., Kilcoyne C.M., and Quyyumi A.A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87 (1993) 1468-1474
25. Panza J.A., Casino P.R., Badar D.M., and Quyyumi A.A. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 87 (1993) 1475-1481
26. Panza J.A., Garcia C.E., Kilcoyne C.M., Quyyumi A.A., and Cannon III R.O. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91 (1995) 1732-1738
27. Sneddon J.M., and Vane J.R. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A 85 (1988) 2800-2804
28. McCall T.B., Boughton-Smith N.K., Palmer R.M., Whittle B.J., and Moncada S. Synthesis of nitric oxide from l-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J 261 (1989) 293-296
29. Kubes P., Suzuki M., and Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88 (1991) 4651-4655
30. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., Beevers D.G., and Lip G.Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87 (2001) 805-807 [A9]
31. Belgore F.M., Lip G.Y., and Blann A.D. Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia. Atherosclerosis 151 (2000) 599
32. Felmeden D.C., Blann A.D., and Lip G.Y. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 24 (2003) 586-603
33. Nadar S.K., Blann A., Beevers D.G., and Lip G.Y. Abnormal angiopoietins 1 and 2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 258 (2005) 336-343